呼吸器感染症診断薬市場：検査、疾患、エンドユーザー別-2025-2030年の世界予測

呼吸器感染症診断薬市場は、2023年に769億4,000万米ドルと評価され、2024年には823億5,000万米ドルに達すると予測され、CAGR 7.15%で成長し、2030年には1,247億8,000万米ドルに達すると予測されています。

調査手法には、インフルエンザ、肺炎、結核、COVID-19などの疾患の診断に使用されるツールや手法が含まれます。その範囲には、ポリメラーゼ連鎖反応（PCR）、迅速抗原検査、血清学などの技術を使用して、原因病原体-ウイルス、細菌、真菌-を特定することが含まれます。呼吸器感染症診断薬の必要性は、特に人口が密集し、免疫力が低下している地域において、公衆衛生に重大な懸念をもたらす感染症の流行と蔓延によって強調されています。調査用途は臨床現場、研究機関、家庭用検査キットなど多岐にわたり、市場の最終用途の広さを際立たせています。成長に影響を与える主な要因としては、迅速診断に対する認識と需要の高まり、技術の進歩、感染症の発生率の上昇などが挙げられます。最近のデジタルヘルス技術と人工知能の進歩は、より正確な診断を可能にし、個別化医療アプローチを促進することで、企業に潜在的なビジネスチャンスをもたらしています。企業は、増大する需要に対応するため、ポータブルで迅速な検査ソリューション、デジタル統合、自動化に投資することが推奨されます。しかし、この市場は、高度な診断に関連する高コスト、規制当局の承認に関する課題、高度に熟練した人材の必要性などの制約に直面しています。これらの要因は、特に新興国市場における市場浸透を制限する可能性があります。企業は、費用対効果が高く、かつ信頼性の高いソリューションに注力することで、こうした課題を克服しなければならないです。さらに、診断の精度とスピードを向上させる必要性があり、統合型POC（ポイント・オブ・ケア）検査機器の開発や、より良いデータ解釈のための機械学習アルゴリズムの活用など、技術革新のための実行可能な領域が存在します。市場競争は激しく、急速に進化しており、イノベーションが重視されているため、既存の障壁に戦略的に対処できる企業にとっては大きなチャンスとなります。市場のダイナミックな性質上、競争力を維持し、世界のヘルスケアニーズに効率的に対応するためには、現在の動向や技術の進歩に遅れを取らないことが必要です。

市場力学：急速に進化する呼吸器感染症診断薬市場の主要市場インサイトを公開

呼吸器感染症診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性閉塞性肺疾患（COPD）の増加
  • 医療インフラの整備と診断方法の増加
  • 感染症診断に対する政府資金の急増
• 市場抑制要因
  • 診断・検査費用の高騰による償還の制限
• 市場機会
  • 呼吸器感染症を診断する次世代シーケンサーベースのプラットフォームの利用可能性
  • 研究開発活動の拡大
• 市場の課題
  • 厳しい規制上の制約

ポーターのファイブフォース：呼吸器感染症診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：呼吸器感染症診断薬市場における外部からの影響の把握

外部マクロ環境要因は、呼吸器感染症診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析呼吸器感染症診断薬市場における競合情勢の把握

呼吸器感染症診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス呼吸器感染症診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、呼吸器感染症診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨呼吸器感染症診断薬市場における成功への道筋を描く

呼吸器感染症診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性閉塞性肺疾患（COPD）の発生率の上昇
    • ヘルスケアインフラの強化と診断手順の利用可能性の両立
    • 感染症診断に対する政府資金の急増
  • 抑制要因
    • 診断と検査のコストが高いため、償還が制限される
  • 機会
    • 呼吸器感染症の診断に次世代シーケンシングベースのプラットフォームが利用可能
    • 研究開発活動の拡大
  • 課題
    • 厳しい規制上の制約
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 呼吸器感染症診断薬市場テスト別

• 抗原検出アッセイ
• 直接蛍光抗体検査
• 画像検査
  • CTスキャン
  • X線
• 体外診断（IVD）検査
• 核酸増幅検査
• 迅速診断テスト

第7章 呼吸器感染症診断薬市場：疾患別

• 喘息
• 慢性閉塞性肺疾患
• コロナウイルス感染症
• エンテロウイルス
• インフルエンザ
• 肺がん
• 肺炎
• 結核
• 百日咳

第8章 呼吸器感染症診断薬市場：エンドユーザー別

• 臨床検査室
• 病院

第9章 南北アメリカの呼吸器感染症診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の呼吸器感染症診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの呼吸器感染症診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AccuBioTech Co. Ltd.
• Atomo Diagnostics Ltd.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• bioMerieux SA
• BIORON Diagnostics GmbH
• Cardinal Health Inc.
• Chembio Diagnostics, Inc.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Merck KGaA
• Meridian Bioscience Inc. by SD Biosensor
• Quest Diagnostics Incorporated
• Quidel Corporation

LIST OF FIGURES

• FIGURE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY INFECTION DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIRECT FLUORESCENT ANTIBODY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CT- SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS (IVD) TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENTEROVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY WHOOPING COUGH (PERTUSSIS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 44. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 66. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 67. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 68. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 70. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 71. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 72. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 139. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 140. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 141. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 155. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 156. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 157. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 159. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 160. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 161. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 199. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Respiratory Infection Diagnostics Market was valued at USD 76.94 billion in 2023, expected to reach USD 82.35 billion in 2024, and is projected to grow at a CAGR of 7.15%, to USD 124.78 billion by 2030.

The respiratory infection diagnostics market encompasses tools and methodologies used to diagnose diseases such as influenza, pneumonia, tuberculosis, and COVID-19, among others. The scope involves identifying causative pathogens-viruses, bacteria, and fungi-using technologies like polymerase chain reaction (PCR), rapid antigen tests, and serology. The necessity of respiratory infection diagnostics is underscored by the prevalence and spread of infections, which pose significant public health concerns, especially in densely populated and immunocompromised regions. Applications span clinical settings, research institutions, and home testing kits, highlighting the market's wide end-use spectrum. Key factors influencing growth include heightened awareness and demand for rapid diagnostics, technological advances, and rising incidences of infectious diseases. The recent advancement in digital health technology and artificial intelligence presents potential opportunities for businesses, enabling more precise diagnosis and facilitating personalized medicine approaches. Companies are recommended to invest in portable and rapid testing solutions, digital integration, and automation to meet the growing demand. However, the market faces limitations such as high costs associated with advanced diagnostics, regulatory approval challenges, and the need for highly skilled personnel. These factors can restrict market penetration, particularly in developing regions. Businesses must navigate these challenges by focusing on cost-effective yet reliable solutions. Additionally, there is an ongoing need for improved diagnostic accuracy and speed, representing viable areas for innovation, such as developing integrated point-of-care (POC) testing devices and leveraging machine learning algorithms for better data interpretation. The respiratory infection diagnostics market is competitive and rapidly evolving, with a strong focus on innovation, thereby presenting a robust opportunity for companies that can strategically address existing barriers. The market's dynamic nature requires staying abreast of current trends and technological advancements to remain competitive and meet global healthcare needs efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Infection Diagnostics Market

The Respiratory Infection Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of chronic obstructive pulmonary disease (COPD)
  • Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
  • Rapid rise in government funding towards infectious disease diagnostics
• Market Restraints
  • High cost of diagnosis and testing limited reimbursement scenarios
• Market Opportunities
  • Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
  • Expanding number of R&D activities
• Market Challenges
  • Strict regulatory constraints

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Infection Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Infection Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Infection Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Infection Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Infection Diagnostics Market

A detailed market share analysis in the Respiratory Infection Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Infection Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Infection Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Infection Diagnostics Market

A strategic analysis of the Respiratory Infection Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Infection Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co. Ltd., Atomo Diagnostics Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, BIORON Diagnostics GmbH, Cardinal Health Inc., Chembio Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Merck KGaA, Meridian Bioscience Inc. by SD Biosensor, Quest Diagnostics Incorporated, and Quidel Corporation.

Market Segmentation & Coverage

This research report categorizes the Respiratory Infection Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test, market is studied across Antigen Detection Assays, Direct Fluorescent Antibody Tests, Imaging Tests, In Vitro Diagnostics (IVD) Tests, Nucleic Acid Amplification Tests, and Rapid Diagnostic Tests. The Imaging Tests is further studied across CT- Scan and X-ray.
• Based on Disease, market is studied across Asthma, Chronic Obstructive Pulmonary Disease, Coronavirus Infections, Enterovirus, Influenza diseases, Lung Cancer, Pneumonia, Tuberculosis, and Whooping Cough (Pertussis).
• Based on End-User, market is studied across Clinical Laboratories and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of chronic obstructive pulmonary disease (COPD)
    • 5.1.1.2. Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
    • 5.1.1.3. Rapid rise in government funding towards infectious disease diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diagnosis and testing limited reimbursement scenarios
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
    • 5.1.3.2. Expanding number of R&D activities
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory constraints
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Respiratory Infection Diagnostics Market, by Test

• 6.1. Introduction
• 6.2. Antigen Detection Assays
• 6.3. Direct Fluorescent Antibody Tests
• 6.4. Imaging Tests
  • 6.4.1. CT- Scan
  • 6.4.2. X-ray
• 6.5. In Vitro Diagnostics (IVD) Tests
• 6.6. Nucleic Acid Amplification Tests
• 6.7. Rapid Diagnostic Tests

7. Respiratory Infection Diagnostics Market, by Disease

• 7.1. Introduction
• 7.2. Asthma
• 7.3. Chronic Obstructive Pulmonary Disease
• 7.4. Coronavirus Infections
• 7.5. Enterovirus
• 7.6. Influenza diseases
• 7.7. Lung Cancer
• 7.8. Pneumonia
• 7.9. Tuberculosis
• 7.10. Whooping Cough (Pertussis)

8. Respiratory Infection Diagnostics Market, by End-User

• 8.1. Introduction
• 8.2. Clinical Laboratories
• 8.3. Hospitals

9. Americas Respiratory Infection Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Infection Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Infection Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AccuBioTech Co. Ltd.
• 3. Atomo Diagnostics Ltd.
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories Inc.
• 6. bioMerieux SA
• 7. BIORON Diagnostics GmbH
• 8. Cardinal Health Inc.
• 9. Chembio Diagnostics, Inc.
• 10. F. Hoffmann-La Roche Ltd.
• 11. Hologic, Inc.
• 12. Merck KGaA
• 13. Meridian Bioscience Inc. by SD Biosensor
• 14. Quest Diagnostics Incorporated
• 15. Quidel Corporation